1. Home
  2. XYF vs NYXH Comparison

XYF vs NYXH Comparison

Compare XYF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$3.45

Market Cap

224.3M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.08

Market Cap

190.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
NYXH
Founded
2014
2009
Country
China
Belgium
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.3M
190.6M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
XYF
NYXH
Price
$3.45
$3.08
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.25
AVG Volume (30 Days)
116.5K
64.0K
Earning Date
03-25-2026
03-19-2026
Dividend Yield
12.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$204.26
Revenue Next Year
N/A
$136.06
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$3.02
52 Week High
$20.36
$8.64

Technical Indicators

Market Signals
Indicator
XYF
NYXH
Relative Strength Index (RSI) 25.52 30.97
Support Level N/A N/A
Resistance Level $5.07 $4.99
Average True Range (ATR) 0.30 0.16
MACD -0.06 0.01
Stochastic Oscillator 1.80 11.67

Price Performance

Historical Comparison
XYF
NYXH

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: